SecBot SecBot
PRESS-RELEASE ·Filed May 15, 2026

CGON

CG Oncology Inc.
BULLISH
Impact 6/10
Horizonweeks Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The strong Phase 2 data enhance the probability of success for cretostimogene in high-risk NMIBC, but the stock already reflects significant optimism (95% analyst buy). Watch for durability data later this year and next catalysts from Phase 3 trials (BOND-003, PIVOT-006).

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$66.93
T+0 close · May 15, 2026 · via day close
Latest settled
+15.09%
T+60 · $77.03
Vs SPY
+10.58%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 15 $66.93entry
  2. T+1 · 6mo ago −5.98%α −5.91% · $62.93
  3. T+5 · 6mo ago −4.00%α −4.97% · $64.25
  4. T+20 · 5mo ago −11.01%α −13.13% · $59.56
  5. T+60 · 3mo ago +15.09%α +10.58% · $77.03
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CG Oncology announced positive Phase 2 data for cretostimogene + gemcitabine in high-risk NMIBC, showing 89.5% HG-EFS at 6 months and 85.7% CR in CIS patients, with no grade 3+ TRAEs. The data support a potential intravesical combination regimen but remain early and require durability follow-up.

Key Facts

  • HG-EFS of 96.0% at 3 months and 89.5% at 6 months in ITT population (median follow-up 6.6 months)
  • CR rate of 85.7% in CIS-containing ITT population (95% CI 67.3%-96.0%) and 92.3% in efficacy-evaluable population (95% CI 74.9%-99.1%)
  • No grade 3 or greater treatment-related adverse events reported; favorable safety profile
  • Data to be presented at AUA 2026; durability data expected later in 2026

Financial Impact

Positive read-through for cretostimogene's commercial potential in NMIBC; no revenue impact yet as product remains investigational

pipeline valueclinical probability of success

Risk Factors

  • Early data with small sample size (28 CIS patients); durability results could disappoint
  • Phase 3 trials (BOND-003, PIVOT-006) still ongoing and may not replicate these results
  • Competitive landscape includes other intravesical therapies (e.g., retifanlimab, targeted agents)

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
95% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3295777

Track record

25 reports on CGON

Performance horizon

6 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 7 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
  2. Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
  3. Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
  4. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
  5. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
  6. Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
  7. Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
  8. Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
  9. Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
  10. Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 6h 22m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026